Literature DB >> 18199158

Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases.

Kennosuke Karube1, Ryosuke Aoki, Yuko Nomura, Kohei Yamamoto, Kay Shimizu, Shirou Yoshida, Hideki Komatani, Yasuo Sugita, Koichi Ohshima.   

Abstract

Although various CD markers have been analyzed in T-cell and natural killer (NK)-cell lymphomas, the sensitivity and specificity of these phenotypic features have not been satisfactorily characterized. Flow cytometry (FCM) was used to determine the phenotypic pattern of 490 T/NK-cell lymphomas with the aid of a set of surface antigens (CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD25, CD30, CD34, and CD56). In data obtained from 319 patients, CD10 expression was detected in 57% of angioimmunoblastic T-cell lymphomas, CD30 in 93% of anaplastic large cell lymphomas, CD34 in 50% of lymphoblastic lymphomas, and CD56 in 100% of extranodal NK/T-cell lymphomas nasal type. A total of 92% of adult T-cell leukemia/lymphomas (ATLL) had expression of CD25 and downregulation of CD7. Of special interest is that 92 ATLL (50%) were CD4+CD7-CD25+ phenotype while only four peripheral T-cell lymphoma unspecified (9%) and one (9%) cutaneous T-cell lymphoma had this phenotype. Phenotypic analysis using FCM was thus found to be useful for differential diagnosis of T-cell and NK-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199158     DOI: 10.1111/j.1440-1827.2007.02195.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  16 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

Review 2.  Follicular helper T cells: implications in neoplastic hematopathology.

Authors:  Philippe Gaulard; Laurence de Leval
Journal:  Semin Diagn Pathol       Date:  2011-08       Impact factor: 3.464

Review 3.  Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma.

Authors:  Manabu Fujisawa; Shigeru Chiba; Mamiko Sakata-Yanagimoto
Journal:  J Clin Exp Hematop       Date:  2017

Review 4.  Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.

Authors:  Lauren Shea; Neha Mehta-Shah
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

5.  Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.

Authors:  Gerald G Wulf; Bettina Altmann; Marita Ziepert; Francesco D'Amore; Gerhard Held; Richard Greil; Olivier Tournilhac; Thomas Relander; Andreas Viardot; Martin Wilhelm; Christian Wilhelm; Antonio Pezzutto; Josee M Zijlstra; Eric Van Den Neste; Pieternella J Lugtenburg; Jeanette K Doorduijn; Michel van Gelder; Gustaaf W van Imhoff; Florian Zettl; Friederike Braulke; Maike Nickelsen; Bertram Glass; Andreas Rosenwald; Philippe Gaulard; Markus Loeffler; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper
Journal:  Leukemia       Date:  2020-05-07       Impact factor: 11.528

Review 6.  CD56-positive adult T-cell leukemia/lymphoma: a case report and a review of the literature.

Authors:  Kei-Ji Sugimoto; Asami Shimada; Mutsumi Wakabayashi; Yasunobu Sekiguchi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ota; Norio Komatsu; Masaaki Noguchi
Journal:  Med Mol Morphol       Date:  2014-03-28       Impact factor: 2.309

7.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2008.

Authors:  J Han J M van Krieken
Journal:  J Hematop       Date:  2008-07       Impact factor: 0.196

8.  Comparative Multi-Epitope-Ligand-Cartography reveals essential immunological alterations in Barrett's metaplasia and esophageal adenocarcinoma.

Authors:  Uta Berndt; Lars Philipsen; Sebastian Bartsch; Yuqin Hu; Christoph Röcken; Wiedenmann Bertram; Marcus Hämmerle; Thomas Rösch; Andreas Sturm
Journal:  Mol Cancer       Date:  2010-07-06       Impact factor: 27.401

9.  Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.

Authors:  Junichi Kiyasu; Hiroaki Miyoshi; Akie Hirata; Fumiko Arakawa; Ayako Ichikawa; Daisuke Niino; Yasuo Sugita; Yuji Yufu; Ilseung Choi; Yasunobu Abe; Naokuni Uike; Koji Nagafuji; Takashi Okamura; Koichi Akashi; Ryoichi Takayanagi; Motoaki Shiratsuchi; Koichi Ohshima
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

10.  Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

Authors:  Steven M Horwitz; Ranjana H Advani; Nancy L Bartlett; Eric D Jacobsen; Jeff P Sharman; Owen A O'Connor; Tanya Siddiqi; Dana A Kennedy; Yasuhiro Oki
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.